Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
-
BUSINESS Shionogi Specialty Squad Providing Deep Info on Mulpleta/Pirespa, Aims for Higher Sales with Fewer Calls
February 26, 2019
-
BUSINESS Takeda Japan Chief Says Shire Buy Only Bolsters Home Operations with No Overlaps, Nixes Job Cuts
February 25, 2019
-
TRENDS Industry Workforce Dwindling as More and More Staffers Take Voluntary Retirement; Astellas Could Cut 700 Jobs
February 22, 2019
-
REGULATORY Kymriah in Line for Japan Approval Next Month as It Gets Key Panel Nod
February 21, 2019
-
REGULATORY Japan to Roll Out Cost-Effectiveness Assessment Scheme in April
February 21, 2019
-
REGULATORY Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
-
COMMENTARY Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul
February 20, 2019
-
ORGANIZATION EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
-
BUSINESS As Japan Goes Digital on Package Inserts, Distributors Fret Proposed Paper-Based Rule on “1st Delivery”
February 18, 2019
-
BUSINESS Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
-
REGULATORY Japan Approves Symbicort Generics, Asthma Drug Stalwart Could Face Competition in June
February 15, 2019
-
BUSINESS Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
-
BUSINESS Recordati Ratcheting Up Japan Biz, Set to Enrich Rare Disease Portfolio
February 14, 2019
-
BUSINESS Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
-
TRENDS Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
February 12, 2019
-
ORGANIZATION 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
-
REGULATORY Importance of Non-ICER Factors in Cost-Effectiveness Assessment Starting to Resonate with Chuikyo Reps
February 7, 2019
-
REGULATORY Kymriah Up for MHLW Panel Review on Feb. 20 as Japan’s 1st CAR-T Therapy
February 6, 2019
-
ORGANIZATION PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…